{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:23:29Z","timestamp":1785432209804,"version":"3.56.0"},"reference-count":13,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Outstanding Young Scholars of Liaoning Province","award":["2019-YQ-10"],"award-info":[{"award-number":["2019-YQ-10"]}]},{"name":"Outstanding Scientific Fund of Shengjing Hospital","award":["201803"],"award-info":[{"award-number":["201803"]}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,1,15]]},"abstract":"<jats:sec id=\"abs1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually subjected to postoperative endocrine therapy (ET). Given that long-term ET can cause severe adverse effects it is important to determine the beneficial effect and safety of post-mastectomy ET on the disease-free survival (DFS) and adverse events in patients with HR+ DCIS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To explore beneficial effect and safety of post-mastectomy ET in patients with HR+ DCIS, we performed a multicenter, population-based study. This retrospective study analyzed the DFS and adverse events in 1037 HR+ DCIS Chinese patients with or without post-mastectomy ET from eight breast centers between 2006 and 2016. The median follow-up time period was 86 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 791 DCIS patients receiving ET (ET group). Those patients were followed up for a median of 86 months (range, 60\u2013177 months). There were 23 cases with tumor recurrence or distant metastasis. There were similar 5-year DFS rates and DFS between the ET and non-ET groups, even for those with high-risk factors. Conversely, 37.04% of patients suffered from adverse events after ET, which were significantly higher than those in the non-ET group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs4\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>ET after mastectomy did not benefit patients with HR+ DCIS for their DFS, rather increased adverse events in those patients. Therefore, ET after mastectomy may not be recommended for patients with HR+ DCIS, even for those with high-risk factors, such as multifocal, microinvasive, and higher T stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs5\">\n                    <jats:title>Funding:<\/jats:title>\n                    <jats:p>This study was supported by grants from Outstanding Scientific Fund of Shengjing Hospital (201803) and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7554\/elife.83045","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T12:15:15Z","timestamp":1673871315000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.83045","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study"],"prefix":"10.7554","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-941X","authenticated-orcid":true,"given":"Nan","family":"Niu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zhang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Bai","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Nursing, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunchao","family":"Yan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Song","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Breast Surgery, the First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d659s21","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Breast Surgery, Liaoning Cancer Hospital and Institute","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05jscf583","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Breast Surgery, Cancer Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hua","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jwb5s28","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03x6hbh34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Breast Surgery, the Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchi","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-921X","authenticated-orcid":true,"given":"Xinbo","family":"Qiao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zheng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wjghj95","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Breast Surgery, the First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Cao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wjghj95","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pathology, the First Affiliated Hospital of China Medical University and College of Basic Medical Sciences","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-235X","authenticated-orcid":true,"given":"Caigang","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1245\/s10434-021-09972-2","article-title":"Ductal carcinoma in situ in young women: increasing rates of mastectomy and variability in endocrine therapy use","volume":"28","author":"Byun","year":"2021","journal-title":"Annals of Surgical Oncology"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","article-title":"Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Ganz","year":"2016","journal-title":"Lancet"},{"key":"bib5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1570","article-title":"Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in england, 1988-2014: population based observational cohort study","volume":"369","author":"Mannu","year":"2020","journal-title":"BMJ"},{"key":"bib6","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8854418","article-title":"Clinicopathological characteristics of breast ductal carcinoma in situ: an analysis of chinese population of 617 patients","volume":"2021","author":"Mao","year":"2021","journal-title":"Journal of Oncology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncology"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1001\/jamaoncol.2016.0525","article-title":"Management of ductal carcinoma in situ of the breast: a review","volume":"2","author":"Shah","year":"2016","journal-title":"JAMA Oncology"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3322\/caac.21321","article-title":"Cancer statistics: breast cancer in situ","volume":"65","author":"Ward","year":"2015","journal-title":"CA"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","article-title":"Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized swedcis trial","volume":"32","author":"W\u00e4rnberg","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"bib13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv263","article-title":"Trends in treatment patterns and outcomes for ductal carcinoma in situ","volume":"107","author":"Worni","year":"2015","journal-title":"Journal of the National Cancer Institute"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/83045\/elife-83045-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/83045\/elife-83045-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/83045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:09:28Z","timestamp":1697058568000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/83045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":13,"alternative-id":["10.7554\/eLife.83045"],"URL":"https:\/\/doi.org\/10.7554\/elife.83045","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.10.06.22280792","asserted-by":"subject"},{"id-type":"doi","id":"10.1101\/2022.10.06.22280792","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.83045.sa0","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.83045.sa1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.83045.sa2","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e83045"}}